Hormone-resistant prostate carcinoma

Summary

Hormone-resistant prostate carcinoma (MONDO:0056814) is a cancer and 56 clinical trials. Top therapeutic interventions include abiraterone acetate, docetaxel anhydrous, and enzalutamide. A subtype of prostate carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 56

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hormone-resistant prostate carcinoma
Mondo ID	MONDO:0056814
NCIT	C114933
UMLS	C3898877
MedGen	858471
Is cancer (heuristic)	yes

Also known as: hormone-resistant prostate cancer · hormone-resistant prostate carcinoma

Disease family

This is a subtype of prostate carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › prostate carcinoma › hormone-resistant prostate carcinoma

Related subtypes (8): prostate squamous cell carcinoma, primary prostate urothelial carcinoma, metastatic prostate carcinoma, prostate adenocarcinoma, grade III prostatic intraepithelial neoplasia, prostate small cell carcinoma, familial prostate carcinoma, castration-resistant prostate carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 56.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	28
Not specified	12
PHASE1/PHASE2	7
PHASE1	6
PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00110214	PHASE3	COMPLETED	Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT01949337	PHASE3	UNKNOWN	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
NCT02312557	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
NCT02881242	PHASE2	ACTIVE_NOT_RECRUITING	Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT00016107	PHASE2	COMPLETED	Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
NCT00040755	PHASE2	COMPLETED	BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00486642	PHASE2	COMPLETED	Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00513071	PHASE2	COMPLETED	AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00541281	PHASE2	COMPLETED	Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
NCT00570700	PHASE2	COMPLETED	Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
NCT00936975	PHASE2	COMPLETED	Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
NCT01026623	PHASE1/PHASE2	COMPLETED	Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
NCT01093183	PHASE1/PHASE2	TERMINATED	Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
NCT01145508	PHASE2	TERMINATED	Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01240629	PHASE1/PHASE2	COMPLETED	Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01253642	PHASE2	TERMINATED	Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
NCT01267266	PHASE2	TERMINATED	Saracatinib in Treating Patients With Prostate Cancer
NCT01270880	PHASE2	COMPLETED	Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
NCT01338792	PHASE2	COMPLETED	Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
NCT01468532	PHASE1/PHASE2	COMPLETED	Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01469338	PHASE2	TERMINATED	Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
NCT01498978	PHASE2	COMPLETED	Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01503229	PHASE2	COMPLETED	Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01519414	PHASE2	COMPLETED	Tivantinib in Treating Patients With Metastatic Prostate Cancer
NCT01533246	PHASE2	COMPLETED	Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
NCT01685125	PHASE2	UNKNOWN	Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01807065	PHASE2	COMPLETED	Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
NCT01848067	PHASE1/PHASE2	COMPLETED	Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
NCT01866423	PHASE2	TERMINATED	Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02012296	PHASE1/PHASE2	COMPLETED	Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
NCT02159950	PHASE2	COMPLETED	Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02215161	PHASE2	TERMINATED	Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
NCT02499835	PHASE1/PHASE2	COMPLETED	Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
NCT02516670	PHASE2	TERMINATED	Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
NCT02844582	PHASE2	TERMINATED	Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02966587	PHASE2	WITHDRAWN	Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02985021	PHASE2	TERMINATED	Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
NCT01174199	PHASE1	TERMINATED	Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
NCT01522820	PHASE1	COMPLETED	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
NCT01913015	PHASE1	TERMINATED	Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ABIRATERONE ACETATE	4	4
DOCETAXEL ANHYDROUS	4	3
ENZALUTAMIDE	4	3
SODIUM FLUORIDE F 18	4	3
BEVACIZUMAB	4	2
CABAZITAXEL	4	2
DASATINIB ANHYDROUS	4	2
PHENELZINE	4	2
SIPULEUCEL-T	4	2
ABIRATERONE	4	1
ACETIC ACID	4	1
BICALUTAMIDE	4	1
ESTRAMUSTINE PHOSPHATE SODIUM	4	1
MIFEPRISTONE	4	1
OCTREOTIDE ACETATE	4	1
PASIREOTIDE	4	1
PAZOPANIB HYDROCHLORIDE	4	1
RALOXIFENE	4	1
SELINEXOR	4	1
TALAZOPARIB	4	1
TEMSIROLIMUS	4	1
TRAMETINIB	4	1
SARACATINIB	3	2
ALISERTIB	3	1
ESTRAMUSTINE	3	1
LINSITINIB	3	1
OCTREOTIDE PAMOATE	3	1
ORTERONEL	3	1
RILIMOGENE GALVACIREPVEC	3	1
SODIUM SELENATE	3	1